- Japan
- /
- Food and Staples Retail
- /
- TSE:3088
An Intrinsic Calculation For MatsukiyoCocokara & Co. (TSE:3088) Suggests It's 22% Undervalued
Key Insights
- Using the 2 Stage Free Cash Flow to Equity, MatsukiyoCocokara fair value estimate is JP¥2,694
- Current share price of JP¥2,114 suggests MatsukiyoCocokara is potentially 22% undervalued
- The JP¥2,799 analyst price target for 3088 is 3.9% more than our estimate of fair value
How far off is MatsukiyoCocokara & Co. (TSE:3088) from its intrinsic value? Using the most recent financial data, we'll take a look at whether the stock is fairly priced by projecting its future cash flows and then discounting them to today's value. The Discounted Cash Flow (DCF) model is the tool we will apply to do this. Before you think you won't be able to understand it, just read on! It's actually much less complex than you'd imagine.
Remember though, that there are many ways to estimate a company's value, and a DCF is just one method. If you want to learn more about discounted cash flow, the rationale behind this calculation can be read in detail in the Simply Wall St analysis model.
Check out our latest analysis for MatsukiyoCocokara
Crunching The Numbers
We're using the 2-stage growth model, which simply means we take in account two stages of company's growth. In the initial period the company may have a higher growth rate and the second stage is usually assumed to have a stable growth rate. In the first stage we need to estimate the cash flows to the business over the next ten years. Where possible we use analyst estimates, but when these aren't available we extrapolate the previous free cash flow (FCF) from the last estimate or reported value. We assume companies with shrinking free cash flow will slow their rate of shrinkage, and that companies with growing free cash flow will see their growth rate slow, over this period. We do this to reflect that growth tends to slow more in the early years than it does in later years.
A DCF is all about the idea that a dollar in the future is less valuable than a dollar today, and so the sum of these future cash flows is then discounted to today's value:
10-year free cash flow (FCF) forecast
2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 | |
Levered FCF (¥, Millions) | JP¥44.7b | JP¥48.3b | JP¥50.3b | JP¥45.3b | JP¥45.6b | JP¥44.8b | JP¥44.3b | JP¥44.0b | JP¥43.8b | JP¥43.7b |
Growth Rate Estimate Source | Analyst x7 | Analyst x8 | Analyst x7 | Analyst x2 | Analyst x2 | Est @ -1.82% | Est @ -1.18% | Est @ -0.74% | Est @ -0.42% | Est @ -0.20% |
Present Value (¥, Millions) Discounted @ 4.3% | JP¥42.8k | JP¥44.4k | JP¥44.4k | JP¥38.3k | JP¥37.0k | JP¥34.8k | JP¥33.0k | JP¥31.4k | JP¥30.0k | JP¥28.7k |
("Est" = FCF growth rate estimated by Simply Wall St)
Present Value of 10-year Cash Flow (PVCF) = JP¥365b
The second stage is also known as Terminal Value, this is the business's cash flow after the first stage. For a number of reasons a very conservative growth rate is used that cannot exceed that of a country's GDP growth. In this case we have used the 5-year average of the 10-year government bond yield (0.3%) to estimate future growth. In the same way as with the 10-year 'growth' period, we discount future cash flows to today's value, using a cost of equity of 4.3%.
Terminal Value (TV)= FCF2034 × (1 + g) ÷ (r – g) = JP¥44b× (1 + 0.3%) ÷ (4.3%– 0.3%) = JP¥1.1t
Present Value of Terminal Value (PVTV)= TV / (1 + r)10= JP¥1.1t÷ ( 1 + 4.3%)10= JP¥722b
The total value, or equity value, is then the sum of the present value of the future cash flows, which in this case is JP¥1.1t. In the final step we divide the equity value by the number of shares outstanding. Relative to the current share price of JP¥2.1k, the company appears a touch undervalued at a 22% discount to where the stock price trades currently. Valuations are imprecise instruments though, rather like a telescope - move a few degrees and end up in a different galaxy. Do keep this in mind.
Important Assumptions
Now the most important inputs to a discounted cash flow are the discount rate, and of course, the actual cash flows. You don't have to agree with these inputs, I recommend redoing the calculations yourself and playing with them. The DCF also does not consider the possible cyclicality of an industry, or a company's future capital requirements, so it does not give a full picture of a company's potential performance. Given that we are looking at MatsukiyoCocokara as potential shareholders, the cost of equity is used as the discount rate, rather than the cost of capital (or weighted average cost of capital, WACC) which accounts for debt. In this calculation we've used 4.3%, which is based on a levered beta of 0.800. Beta is a measure of a stock's volatility, compared to the market as a whole. We get our beta from the industry average beta of globally comparable companies, with an imposed limit between 0.8 and 2.0, which is a reasonable range for a stable business.
SWOT Analysis for MatsukiyoCocokara
- Earnings growth over the past year exceeded the industry.
- Debt is not viewed as a risk.
- Dividends are covered by earnings and cash flows.
- Earnings growth over the past year is below its 5-year average.
- Dividend is low compared to the top 25% of dividend payers in the Consumer Retailing market.
- Annual earnings are forecast to grow for the next 3 years.
- Good value based on P/E ratio and estimated fair value.
- Annual earnings are forecast to grow slower than the Japanese market.
Next Steps:
Although the valuation of a company is important, it ideally won't be the sole piece of analysis you scrutinize for a company. DCF models are not the be-all and end-all of investment valuation. Rather it should be seen as a guide to "what assumptions need to be true for this stock to be under/overvalued?" If a company grows at a different rate, or if its cost of equity or risk free rate changes sharply, the output can look very different. Can we work out why the company is trading at a discount to intrinsic value? For MatsukiyoCocokara, we've compiled three further items you should further examine:
- Financial Health: Does 3088 have a healthy balance sheet? Take a look at our free balance sheet analysis with six simple checks on key factors like leverage and risk.
- Future Earnings: How does 3088's growth rate compare to its peers and the wider market? Dig deeper into the analyst consensus number for the upcoming years by interacting with our free analyst growth expectation chart.
- Other High Quality Alternatives: Do you like a good all-rounder? Explore our interactive list of high quality stocks to get an idea of what else is out there you may be missing!
PS. Simply Wall St updates its DCF calculation for every Japanese stock every day, so if you want to find the intrinsic value of any other stock just search here.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About TSE:3088
MatsukiyoCocokara
Operates and manages a chain of drug stores and health insurance prescription pharmacies in Japan.
Excellent balance sheet average dividend payer.